Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E15.79 EPS (ttm)6.22 Insider Own0.10% Shs Outstand1.59B Perf Week0.69%
Market Cap156.32B Forward P/E11.02 EPS next Y8.91 Insider Trans-11.91% Shs Float1.59B Perf Month-7.51%
Income9.96B PEG0.95 EPS next Q1.98 Inst Own71.70% Short Float2.74% Perf Quarter-12.63%
Sales29.61B P/S5.28 EPS this Y52.60% Inst Trans-0.55% Short Ratio4.75 Perf Half Y0.06%
Book/sh2.23 P/B44.06 EPS next Y14.36% ROA9.20% Target Price113.86 Perf Year37.95%
Cash/sh5.95 P/C16.50 EPS next 5Y16.70% ROE119.30% 52W Range69.38 - 125.86 Perf YTD1.59%
Dividend3.84 P/FCF27.27 EPS past 5Y10.60% ROI25.40% 52W High-21.94% Beta1.59
Dividend %3.91% Quick Ratio1.10 Sales past 5Y9.00% Gross Margin75.80% 52W Low41.61% ATR1.87
Employees29000 Current Ratio1.20 Sales Q/Q21.40% Oper. Margin34.00% RSI (14)46.84 Volatility1.48% 1.84%
OptionableYes Debt/Eq10.49 EPS Q/Q64.20% Profit Margin21.50% Rel Volume0.51 Prev Close98.01
ShortableYes LT Debt/Eq8.70 EarningsJul 26 BMO Payout65.90% Avg Volume9.15M Price98.25
Recom2.40 SMA20-1.98% SMA50-0.84% SMA200-0.97% Volume4,681,430 Change0.24%
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-20-18 08:07AM  5 Experimental New Drugs That Could Be Worth $47 Billion Motley Fool
06:01AM  Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks Motley Fool
Jun-19-18 09:21AM  8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities" PR Newswire
07:20AM  Wired News AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress ACCESSWIRE
06:32AM  3 Great Reasons to Buy Gilead Sciences Motley Fool
Jun-18-18 06:23PM  Bristol-Myers Posts Data on Empliciti, China Approves Opdivo Zacks
10:30AM  How U.S. tax reform rewards companies that shift profit to tax havens Reuters
08:20AM  Today's Research Reports on Trending Tickers: Canopy Growth and AbbVie ACCESSWIRE
Jun-17-18 12:03PM  Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming Motley Fool
Jun-15-18 10:26AM  MARKETS: Here's why stocks are dropping right now Yahoo Finance Video
09:27AM  Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals Zacks
09:01AM  3 High-Yield Stocks at Rock-Bottom Prices Motley Fool
08:18AM  Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc Motley Fool
07:35AM  Analysis: Positioning to Benefit within Canopy Growth, Aurora Cannabis, CannTrust, AbbVie, Cronos Group, and Scotts Miracle-Gro Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
02:45AM  AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress PR Newswire
Jun-14-18 06:52PM  AbbVie Declares Quarterly Dividend PR Newswire
Jun-13-18 06:01AM  Humira's Sales Will Decline -- and It's Fantastic News for AbbVie Motley Fool
Jun-12-18 06:38PM  AbbVie Presents Additional Outcomes Data from Three Upadacitinib Phase 3 Studies in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR 2018) PR Newswire
Jun-11-18 10:00AM  Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval Zacks
09:37AM  JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space Zacks
09:08AM  The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AbbVie Zacks
Jun-10-18 05:29PM  The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs Benzinga
09:40AM  3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate Motley Fool
Jun-09-18 08:36AM  4 Dividends That Make The World A Better Place Forbes
Jun-08-18 02:55PM  AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy PR Newswire
10:27AM  Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant Zacks
Jun-07-18 11:30AM  [$$] Big Pharma's Tempting Payouts
Jun-06-18 09:24AM  Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive Zacks
08:29AM  ASCO Ends: Winners & Losers at the Key Cancer Research Event Zacks
06:02AM  2 Cheap Dividend Stocks You Can Buy Right Now Motley Fool
Jun-05-18 09:16AM  AbbVie's rheumatoid arthritis drug succeeds in late-stage study Reuters
08:30AM  Upadacitinib Monotherapy Meets All Primary and Ranked Secondary Endpoints Versus Methotrexate in a Phase 3 Study in Rheumatoid Arthritis PR Newswire
Jun-04-18 08:30AM  Today's Research Reports on Trending Tickers: AbbVie and TherapeuticsMD ACCESSWIRE
08:00AM  AbbVie Announces Final Results of Tender Offer PR Newswire
Jun-03-18 05:52PM  Benzinga's Bulls & Bears Of The Week: AbbVie, Lululemon, Netflix, Snap And More Benzinga
10:45AM  Phase 2 IMBRUVICA® (ibrutinib) Plus VENCLEXTA® (venetoclax) Early Data Show High Rates of Responses in Patients with Previously-Untreated Chronic Lymphocytic Leukemia (CLL) PR Newswire
Jun-01-18 04:45PM  Phase 3 IMBRUVICA® (ibrutinib) Data Suggest Improved Treatment Outcomes in Waldenström's Macroglobulinemia (WM), a Rare Form of Blood Cancer, in Combination with Rituximab versus Rituximab Alone PR Newswire
01:47PM  How Novartis, Insurers Are Taking Wind Out Of AbbVie's Sales Investor's Business Daily
09:15AM  Solid Month Ends with New Round of Trade Fears Zacks
09:03AM  Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod Reuters
08:54AM  Novartis, aiming to go toe-to-toe with Humira, wins EU panel nod Reuters
May-31-18 11:24AM  Traders Are Furious After Computer Botches Stock Sale Bloomberg
09:05AM  Thursdays Vital Data: Micron Technology, Inc. (MU), Bank of America Corp (BAC) and AbbVie Inc. (ABBV) InvestorPlace
08:00AM  AbbVie to Present New Data from Several Investigational Studies of Venetoclax as Monotherapy or in Combination for the Management of a Number of Difficult-to-Treat Blood Cancers at 23rd European Hematology Association (EHA) Annual Congress PR Newswire
May-30-18 04:46PM  AbbVie Announces Updated Preliminary Results of Tender Offer PR Newswire
04:36PM  Why AbbVie's Blockbuster Humira Is Already In Trouble This Year Investor's Business Daily
12:28PM  Credit Suisse Downgrades AbbVie On Humira Competitive Concerns Benzinga
08:00AM  AbbVie Announces Preliminary Results of Tender Offer PR Newswire
06:01AM  Is AbbVie Inc. (ABBV) a Buy? Motley Fool
May-29-18 09:57AM  What's in Store for Cooper Companies' (COO) Q2 Earnings? Zacks
08:00AM  AbbVie to Present at the Goldman Sachs 39th Annual Global Healthcare Conference PR Newswire
May-28-18 02:46AM  AbbVie (ABBV) Up 5.9% Since Earnings Report: Can It Continue? Zacks
May-25-18 09:24AM  AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint Zacks
May-24-18 04:14PM  AbbVie Is The Amazon Of Biopharma But Can It Keep Going? Investor's Business Daily
09:00AM  IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint PR Newswire
08:35AM  Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock? Zacks
08:00AM  Wired News CytomX Gets FDA Approval for Investigational New Drug Application, Triggers $25 Million Milestone Payment from AbbVie ACCESSWIRE
May-23-18 06:01AM  Better Buy: AbbVie Inc. vs. Pfizer Inc. Motley Fool
May-22-18 10:30AM  AbbVie Donates $100 Million to Strengthen Access to Healthcare, Housing for Hurricane-Ravaged Puerto Rico PR Newswire
08:00AM  AbbVie to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
07:47AM  The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo Zacks
May-21-18 02:25PM  Roche (RHHBY) Announces Positive Data on Hemophilia Drug Zacks
10:53AM  Top Analyst Reports for Procter & Gamble, AbbVie, McDonald's & PepsiCo Zacks
07:15AM  Bristol-Myers Squibb and Three Additional Stocks Under Scanner in the Drug Makers Space ACCESSWIRE
May-18-18 08:15AM  5 Things AbbVie Investors Need to Know Motley Fool
May-16-18 04:59PM  AbbVie to Show Progress and Growth in Oncology Research at the American Society of Clinical Oncology 2018 Annual Meeting PR Newswire
May-15-18 05:09PM  Trumps Attempt to Shame Drugmakers Shows Medicare Costs Soaring Bloomberg
06:00AM  3 Top Healthcare Stocks to Buy in May Motley Fool
May-14-18 01:25PM  The Trump Plan To Reduce Prescription Drug Prices Will Have A Major Impact Forbes
May-11-18 04:02PM  Why Do 113 Top-Rated Funds Own Shares In This Breakout Cloud Stock? Investor's Business Daily
May-10-18 06:49PM  3 Dividend Stocks for In-the-Know Investors Motley Fool
May-09-18 06:00AM  3 Top Biotech Stocks to Buy in May Motley Fool
May-08-18 08:00AM  AbbVie to Present at the UBS Global Healthcare Conference PR Newswire
May-04-18 04:06PM  Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication Zacks
07:00AM  Is Gilead Sciences Stock Finally a Bargain? Motley Fool
May-03-18 01:58PM  Top 5 Biotech Stocks for 2018 Investopedia
10:23AM  Did Gilead Sciences Make a Big Mistake? Motley Fool
10:15AM  NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth Zacks Small Cap Research
09:11AM  Drugmakers eye a new threat to sales but say it hasnt affected them yet MarketWatch
08:45AM  Your first trade for Thursday, May 3 CNBC
May-02-18 05:59PM  "Fast Money" final trades: SNAP, SPOT and more CNBC Videos
05:15PM  Top 4 Marijuana Stocks to Watch Investopedia
01:39PM  9 Winning Stocks as the Bull Loses Steam Investopedia
08:00AM  AbbVie to Present at the 2018 Bank of America Merrill Lynch Health Care Conference PR Newswire
06:03AM  Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV) Motley Fool
06:01AM  Gilead Sciences' First-Quarter Twist: Weak HIV Sales Motley Fool
May-01-18 04:33PM  Seagate, Pfizer and Cummins skid while AbbVie jumps Associated Press +5.72%
04:31PM  Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today Motley Fool
09:32AM  How AbbVie Makes its Money Investopedia
08:45AM  AbbVie Submits Marketing Authorization Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis PR Newswire
07:47AM  AbbVie Commences Self-Tender Offer for Up to $7.5 Billion of its Common Stock PR Newswire
04:31AM  [$$] Gilead shares rattled by sharp slide in hepatitis C drug sales Financial Times
Apr-30-18 11:35AM  AbbVie and Rice University establish K.C. Nicolaou Research Accelerator to advance therapies in oncology PR Newswire
10:11AM  Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More Zacks
Apr-28-18 02:03PM  AbbVie's First Quarter: Can We Quit Worrying About Humira Now? Motley Fool
Apr-27-18 08:18AM  3 Things You Need to Know About AbbVie's Monster Q1 Earnings Motley Fool
08:00AM  AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting PR Newswire
Apr-26-18 11:59PM  Edited Transcript of ABBV earnings conference call or presentation 26-Apr-18 1:00pm GMT Thomson Reuters StreetEvents +6.06%
04:29PM  How AbbVie 'Crushed It' On Hepatitis C As Fellow Drugmaker Bristol Dips Investor's Business Daily
02:23PM  AbbVie Inc. -- Moody's: AbbVie's share repurchase acceleration credit negative Moody's
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; and International Myeloma Foundation. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM
Schumacher Laura JExecutive Vice PresidentDec 14Option Exercise35.88144,3675,179,888250,099Dec 15 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM